{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:31:43Z","timestamp":1788496303579,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin Pharmaceutical Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the objective of sharing these practice-based insights on the use of burosumab in children and adolescents with XLH. We attended two virtual meetings, then discussed key questions <jats:italic>via<\/jats:italic> Within3, a virtual online platform. Points of discussion related to patient selection criteria, burosumab starting dose, dose titration and treatment monitoring. Our discussions revealed that criteria for selecting children with XLH varied across Europe from all children above 1 year to only children with overt rickets despite conventional treatment being eligible. We initiated burosumab dosing according to guidance in the Summary of Product Characteristics, an international consensus statement from 2019 and local country guidelines. Dose titration was primarily guided by serum phosphate levels, with some centers also using the ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP\/GFR). We monitored response to burosumab treatment clinically (growth, deformities, bone pain and physical functioning), radiologically (rickets and deformities) and biochemically (serum phosphate, alkaline phosphatase, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, urine calcium-creatinine ratio and TmP\/GFR). Key suggestions made by our group were initiation of burosumab treatment in children as early as possible, from the age of 1 year, particularly in those with profound rickets, and a need for clinical studies on continuation of burosumab throughout adolescence and into adulthood.<\/jats:p>","DOI":"10.3389\/fendo.2022.1034580","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T14:12:35Z","timestamp":1675174355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries"],"prefix":"10.3389","volume":"13","author":[{"given":"M. Zulf","family":"Mughal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero I.","family":"Baroncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"de Lucas-Collantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Magnolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalbert","family":"Raimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02465-x","article-title":"Exploring the burden of X-linked hypophosphatemia: A European multi-country qualitative study","volume":"29","author":"Lo","year":"2020","journal-title":"Qual Life Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: A retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"435\u2012455","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa151","article-title":"X-Linked hypophosphatemia: A new era in management","author":"Dahir","year":"2020","journal-title":"J Endocr Soc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.119","article-title":"Dental abnormalities in patients with familial hypophosphatemic vitamin d-resistant rickets: Prevention by early treatment with 1-hydroxyvitamin d","volume":"142","author":"Chaussain-Miller","year":"2003","journal-title":"J Pediatr"},{"key":"B7","first-page":"61\u201266","article-title":"Prevalence and pathogenesis of dental and periodontal lesions in children with X-linked hypophosphatemic rickets","volume":"7","author":"Baroncelli","year":"2006","journal-title":"Eur J Paediatr Dent"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-020-01136-8","article-title":"Pulp chamber features, prevalence of abscesses, disease severity, and PHEX mutation in X-linked hypophosphatemic rickets","author":"Baroncelli","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"R13\u2012R30","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00338","article-title":"Clinical evidence for the benefits of burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children","volume":"11","author":"Schindeler","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations","volume":"9","author":"Padidela","year":"2020","journal-title":"Endocr Connect"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1987\u20121998","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: A multicentre, open-label, phase 2 trial","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2416\u20122427","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"B16","volume-title":"CRYSVITA\u00ae (burosumab) summary of product characteristics","year":"2021"},{"key":"B17","doi-asserted-by":"publisher","first-page":"271\u2012284","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: Results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2183\u20122191","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: A phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac296","article-title":"Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia","volume":"107","author":"Ward","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05484-7","article-title":"Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets","volume":"37","author":"Paloian","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.15976","article-title":"Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab","volume":"58","author":"Sandy","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"B23","first-page":"226","article-title":"BUR-CL207: An open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics and efficacy of burosumab in pediatric patients from birth to less than 1 year of age with XLH","volume":"94","author":"Padidela","year":"2021","journal-title":"Horm Res Paediatr"},{"key":"B24","unstructured":"Burosumab for treating X-linked hypophosphataemia in children and young people2018"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105208","article-title":"X-Linked hypophosphatemia and burosumab: Practical clinical points from the French experience","volume":"88","author":"Bacchetta","year":"2021","journal-title":"Joint Bone Spine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30426-7","article-title":"Approach to patients with hypophosphataemia","volume":"8","author":"Florenzano","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0736","article-title":"Current vitamin d status in European and middle East countries and strategies to prevent vitamin d deficiency: A position statement of the European calcified tissue society","volume":"180","author":"Lips","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02156-x","article-title":"Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH)","volume":"17","author":"Glorieux","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1249\u20121256","DOI":"10.1111\/apa.15617","article-title":"A cross-sectional magnetic resonance imaging study of factors influencing growth plate closure in adolescents and young adults","volume":"110","author":"Kvist","year":"2021","journal-title":"Acta Paediatr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0429","article-title":"Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia","volume":"185","author":"Zhukouskaya","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000464142","article-title":"Magnetic resonance imaging features as surrogate markers of X-linked hypophosphatemic rickets activity","volume":"87","author":"Lempicki","year":"2017","journal-title":"Horm Res Paediatr"},{"key":"B32","unstructured":"About us. what we do"},{"key":"B33","unstructured":"Health technology assessment"},{"key":"B34","doi-asserted-by":"publisher","first-page":"93\u2012103","DOI":"10.1016\/j.clinbiochem.2017.12.011","article-title":"CLSI-based transference and verification of CALIPER pediatric reference intervals for 29 ortho VITROS 5600 chemistry assays","volume":"53","author":"Higgins","year":"2018","journal-title":"Clin Biochem"},{"key":"B35","first-page":"89\u201296","article-title":"Closing the gaps in paediatric reference intervals: the CALIPER initiative","volume":"29","author":"Schnabl","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"B36","first-page":"2122","article-title":"Unresponsiveness to treatment with burosumab in patients with X- linked hypophosphatemia (XLH)","author":"Eggert","year":"2019"},{"key":"B37","first-page":"1873","article-title":"Response to burosumab in children with X-linked hypophosphataemia","volume":"34","author":"Wallace","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B38","first-page":"P765","article-title":"Clinical responses in adult XLH patients not achieving consistent serum phosphate normalisation: A subgroup analysis of a randomised, double-blind, placebo-controlled, phase III study. Presented at: ASBMR virtual event; September 11\u201315 (2020)","author":"Brandi","year":""},{"key":"B39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11657-021-00879-9","article-title":"Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the gulf cooperation council countries","volume":"16","author":"Al Juraibah","year":"2021","journal-title":"Arch Osteoporos"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9613","DOI":"10.1038\/s41598-017-10110-w","article-title":"Effective method for drug injection into subcutaneous tissue","volume":"7","author":"Kim","year":"2017","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J Trop Pediatr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"868\u2012874","DOI":"10.1002\/jbmr.3377","article-title":"Validation of a novel scoring system for changes in skeletal manifestations of hypophosphatasia in newborns, infants, and children: The radiographic global impression of change scale","volume":"33","author":"Whyte","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1159\/000464142","article-title":"Magnetic resonance imaging features as surrogate markers of X-linked hypophosphatemic rickets activity","author":"Lempicki","year":"2017","journal-title":"Horm Res Paediatr"},{"key":"B44","doi-asserted-by":"publisher","first-page":"133\u2012143","DOI":"10.1002\/jmri.26771","article-title":"Status of growth plates can be monitored by MRI","volume":"51","author":"Wada","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2020.07.007","article-title":"Disease-specific gait deviations in pediatric patients with X-linked hypophosphatemia","volume":"81","author":"Mindler","year":"2020","journal-title":"Gait Posture"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1381\u20121388","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.23937\/2643-4571\/1710029","article-title":"Defining a growing and maturing skeleton and its relevance in diseases that affect skeletal growth, such as X-linked hypophosphataemia (XLH)","volume":"4","author":"Beck-Nielsen","year":"2021","journal-title":"Int J Rare Dis Disord"},{"key":"B48","doi-asserted-by":"publisher","first-page":"669\u2012679","DOI":"10.1002\/ajhb.1310050609","article-title":"Improvement in the Roche-Wainer-Thissen stature prediction model: A comparative study","volume":"5","author":"Khamis","year":"1993","journal-title":"Am J Hum Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00457","article-title":"Delphi Technique in health sciences: A map","volume":"8","author":"Niederberger","year":"2020","journal-title":"Front Public Health"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1034580\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T14:12:46Z","timestamp":1675174366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1034580\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":49,"alternative-id":["10.3389\/fendo.2022.1034580"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1034580","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"article-number":"1034580"}}